The adhesives maker raised its EBITDA outlook as Q2 2026 results exceeded guidance amid an acquisition push.
H.B. Fuller (FUL) announced a $650M-$675M EBITDA range for fiscal year 2026, reflecting confidence in growth following a strong Q2 performance. The company reported EBITDA above the midpoint of its prior guidance, driven by year-on-year revenue and earnings growth.
In Q2 2026, H.B. Fuller delivered results surpassing internal expectations, with management citing execution and market demand as key factors. The updated EBITDA range follows the company’s acquisition of Advanced Medical Solutions, which is expected to bolster its portfolio.
No immediate market reaction was disclosed in the earnings call summary.